(Q40780575)

English

Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials (English)

1 reference

Europe PubMed Central

23 September 2017

0 references

polycystic liver disease

1 reference

based on heuristic

inferred from title

author name string

M K Neijenhuis

1

1 reference

Europe PubMed Central

23 September 2017

T J G Gevers

2

1 reference

Europe PubMed Central

23 September 2017

F Nevens

3

1 reference

Europe PubMed Central

23 September 2017

M C Hogan

4

1 reference

Europe PubMed Central

23 September 2017

V E Torres

5

1 reference

Europe PubMed Central

23 September 2017

W Kievit

6

1 reference

Europe PubMed Central

23 September 2017

J P H Drenth

7

1 reference

Europe PubMed Central

23 September 2017

language of work or name

0 references

publication date

1 July 2015

1 reference

Europe PubMed Central

23 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

23 September 2017

42

1 reference

Europe PubMed Central

23 September 2017

591-598

1 reference

Europe PubMed Central

23 September 2017

5

1 reference

Europe PubMed Central

23 September 2017

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Liver involvement in early autosomal-dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Medical and surgical treatment options for polycystic liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Diagnosis and management of polycystic liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

A 20-year experience with liver transplantation for polycystic liver disease: does previous palliative surgical intervention affect outcomes?

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Somatostatin analogues for treatment of polycystic liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trials.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Diagnostic studies as multivariable, prediction research

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

A review of health utilities using the EQ-5D in studies of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

A comparison of the responsiveness of different generic health status measures in patients with asthma.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Laparoscopic fenestration of non-parasitic liver cysts and health-related quality of life assessment

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Surgical management and longterm follow-up of non-parasitic hepatic cysts

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Individual quality of life in patients undergoing hip replacement

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13301

21 January 2018

Identifiers

10.1111/APT.13301

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40780575&oldid=1907309186"